Table 2.
Antiretroviral therapy
| Treatment regimen | SOF/LDV | 2D/3D |
|---|---|---|
| 3TC | 6 (28.6%) | 7 (46.6%) |
| ABC | 5 (23.8%) | 7 (46.6%) |
| TDF | 15 (71.4%) | 8 (53.3%) |
| FTC | 14 (66.7%) | 8 (53.3%) |
| ATZ | 1 (4.8%) | 1 (6.7%) |
| DRV | 2 (9.5%) | 0 |
| FPV | 1 (4.8%) | 0 |
| RTV | 4 (19.0%) | 1 (6.7%) |
| RPV | 1 (4.8%) | 1 (6.7%) |
| ETR | 2 (9.5%) | 0 |
| RAL | 5 (23.8%) | 3 (20%) |
| DTG | 10 (47.6%) | 10 (66.7%) |
3TC lamivudine, ABC abacavir, TDF tenofovir disoproxil fumarate, FTC emtricitabine, ATZ atazanavir, DRV darunavir, FPV fosamprenavir, RTV ritonavir, RPV rilpivirine, ETR etravirine, RAL raltegravir, DTG dolutegravir